Peripheral Arterial Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have a confirmed diagnosis (proven by biopsy) of systemic AL amyloidosis, POEMS syndrome, or multiple myeloma
- People who are already scheduled to have a blood sample taken from a vein, and possibly also a bone marrow sample, as part of their usual care
- People who are 18 years of age or older
- People who are willing to sign a consent form allowing their clinical information and leftover diagnostic samples to be used for research
Who may not be able to join:
- People whose condition has been identified as an undefined monoclonal gammopathy (an uncertain protein abnormality in the blood) or a type of amyloidosis that is not AL amyloidosis (confirm with trial site)
- People whose blood cancer or related condition has already reached a complete response to treatment (meaning tests show no remaining signs of the abnormal cells after therapy)
- People who are under 18 years of age
- People who are not willing to allow their clinical data and leftover diagnostic samples to be used for research purposes
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 0382502935
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
identify sequence fingerprints in IGLV1-44 light chains leading to AL amyloidosis and POEMS syndrome
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.